LIVTENCITY

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, France, Israel, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug LIVTENCITY contains one active pharmaceutical ingredient (API):

1	Maribavir UNII PTB4X93HE1 - MARIBAVIR
	Maribavir is a competitive inhibitor of the UL97 protein kinase. UL97 inhibition occurs at the viral DNA replication phase, inhibiting UL97 serine/threonine kinase by competitively inhibiting the binding of ATP to the kinase ATP-binding site, without affecting the concatemer maturation process, abolishing phosphotransferase inhibiting CMV DNA replication and maturation, CMV DNA encapsidation, and CMV DNA nuclear egress.
	Read more about Maribavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIVTENCITY Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AX10		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02530740
ES	Centro de información online de medicamentos de la AEMPS	1221672002
FR	Base de données publique des médicaments	66919901
IL	מִשְׂרַד הַבְּרִיאוּת	9220
IT	Agenzia del Farmaco	050317015, 050317027, 050317039
LT	Valstybinė vaistų kontrolės tarnyba	1095951, 1095952
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69408001, W69408002
US	FDA, National Drug Code	64764-800